"Concerned" J&J hopes to stop monthly Tylenol recalls

The most recent recall of Children's Tylenol and related products is "a matter of great concern," writes Johnson & Johnson CEO Bill Weldon on a company blog. In a sustained GMP embarrassment, the late April recall marks the fourth such Tylenol action in as many months. It follows the mid-March move of quality VP Veronica Cruz to McNeil from J&J, and it precedes McNeil's hiring of independent quality experts. That's a lot of QC horsepower rolling into May, the fifth month; hopefully it will forestall a fifth Tylenol recall. Blog | Item

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.